GenVinSet

HLA B57v5

Instructions for use

Kit for the detection of the HLA-B*57:01 alleles

For In Vitro Diagnostics Use

Product code GVS-B5705-48 (48 test)
GVS-B5705-24 (24 test)

Store from –18 to –30ºC

Rev03/08-04-2021

Blackhills Diagnostic Resources, S.L.U.
Camino del Pilón 86, Casa 7 Local. 50011- Zaragoza -Spain
www.bdrdiagnostics.com

GenVinSet

HLA B57v5

Index

Intended use 3

Summary and explanation 4

Procedure principles 5

Kit contents 6

Kit storage 7

Materials required but not supplied 8

Sample collection and preparation 9

Usage procedures 10

A) PCR setup

B) Thermal cycler configuration

Results 12

Quality control 13

Specific operation data 14

Family of HLA-B*57 alleles (IMGT-HLA 3.43.0) detected by the Genvinset®HLA B57v5 kit 15

Limitations of the procedure 18

Troubleshooting guide 19

References 21

Notice to purchaser 22

Changes to version 01 23

Explanation of symbols used on the labels 24

BDR

Blackhills Diagnostic Resources

Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

Intended use

Genvinset® HLA B57v5 is a kit for the determination of the HLA-B*57:01 allele by Real time PCR using Taqman® probes technology.

BDR
Blackhills Diagnostic Resources

Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

Summary and explanation

Abacavir sulfate is a synthetic carboxylic nucleoside drug, which works as a reverse transcriptase inhibitor and is used to treat HIV (human Immunodeficiency Virus).

This drug has been associated with the occurrence of fatal hypersensitivity reaction. Symptoms include fever, skin rash, fatigue, gastrointestinal symptoms such as nausea, vomiting, diarrhea or abdominal pain. Other respiratory symptoms such as pharyngitis, dyspnea or cough are also associated. The aforementioned hypersensitivity has been related to the HLA-B*57:01 allele so, before starting the abacavir treatment, it is recommended to perform a study to determine the presence or absence of the allele in the patient.

The HLA-B*57:01 allele is a polymorphism of the HLA-B gene, which belongs to the class I MHC (Major Histocompatibility complex). This allele shows a frequency of around 3% in the European population.

BDR
Blackhills Diagnostic Resources
Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

Procedure principles

The detection method used by Genvinset® is based on the Real Time PCR technology, monitored with Taqman® probes.

The Genvinset® HLA B57v5 kit allows for the determination of the HLA-B*57:01(*) allele and a control gene (ß-Globin), used to verify the results of the assay.

Each pair of primers is complementary to two DNA sequences, located in cis, thus making of the current kit a high resolution technique with high sensitivity, specificity and reproducibility.

(*) See section 'Limitations of the Procedure'.

BDR
Blackhills Diagnostic Resources
Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

Kit contents

Product code GVS-B5705-48 (48 tests)

- GVS-B57v5-PM: 2 x 220 µL Primer Mix (PM).
- GVS-B57v5-MM: 2 x 276 µL Master Mix (MM)
- GVS-B57v5-C+: 1 x 10 µL Positive Control (C+)
- GVS-RB: 1 x 100 µL Reaction Blank (RB)

Product code GVS-B5705-24 (24 tests)

- GVS-B57v5-PM: 1 x 220 µL Primer Mix (PM).
- GVS-B57v5-MM: 1 x 276 µL Master Mix (MM)
- GVS-B57v5-C+: 1 x 10 µL Positive Control (C+)
- GVS-RB: 1 x 100 µL Reaction Blank (RB)

BDR
Blackhills Diagnostic Resources
Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

Kit storage

In order to ensure a proper performance, reagents should be stored from -18ºC to -30ºC until their expiration date, indicated on the label of the vial. Do not perform more than 3 freeze/thaw cycles to the Primer Mix (GVS-B57v5-PM) and Master Mix (GVS-B57v5-MM) vials, as this could decrease the sensitivity of the assay and impair results.

Due to the reagent's photosensitivity nature, avoid continuous exposure to light.

BDR
Blackhills Diagnostic Resources
Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

Materials required but not supplied

General

- Gloves
- Lab coat

Consumables

- Filter tips (P200, P100 and P10)
- 1,5 mL Autoclaved tubes
- q-PCR instrument specific reagents (in the case of using Rotor-Gene® Q, only 0.1 mL tubes are allowed).

Equipment

- q-PCR instrument, with FAM and HEX/VIC detection channels. The following devices have been validated:
  - Rotor-Gene® Q, Qiagen®
  - DTlite, DNA Technologies
  - QTower, Analytic Jena
  - 7500 Real-Time PCR System, Applied Biosystems™
  - LightCycler® 96 System, Roche
  - QuantStudio 6, Applied Biosystems™
- Vortex mixer
- Pipettes (P200, P100 and P10)

BDR
Blackhills Diagnostic Resources
Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

Sample collection and preparation

This test should only be performed with complete blood samples treated with EDTA anti coagulation agents or citrate. Heparin can interfere with the PCR process and should not be used in this procedure.

The technique is compatible with any conventional DNA extraction system. Before delivering results with a diagnostic purpose, a validation assay with such extraction method should be done.

Caution

All biological and blood samples should be treated as potencially infectious. All the corresponding basic (universal) precautions should be taken. Samples should always be handled wearing the appropriate personal protection equipment.

BDR
Blackhills Diagnostic Resources
Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

Usage procedures

A) PCR setup

Precautions

- Thaw all components of the kit before starting the assay, mix and centrifuge them.
- Work on ice or over a cool block.
- The PCR should be set up in the Pre-PCR area.
- Use only filtered tips and autoclaved tubes 1,5 mL.
- Use gloves and lab coat at all times.
- In each session it is recommended to test the contamination control (Reaction Blank) and the Positive Control (B*57:01+) included in the kit, as well as a B*57:01 negative sample.

1. Thaw the samples. Vortex (or gently mix with the fingers).
2. Prepare the following mix for n+1 samples:

	Vol. per sample (µL)
Master Mix	10
Primer Mix	8

3. Pipette 18 µL of the mix in each well. Then add 2 µL of DNA, Positive Control or Reaction Blank in the corresponding well.
4. Seal the plate or the tubes. Perform a brief spin to ensure that all the volume settles to the bottom of the tube.
5. Place the plate in the thermocycler and start the following program.

BDR
Blackhills Diagnostic Resources
Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

B) Thermal cycler configuration

1. Set up the following amplification program:

2. Set up the reading channels as indicated below:

	Cycle number	Temperature (ºC)	Time (mm:ss)	Ramp (%)	Analysis
Denaturation	1	95	05:00	100	X
Cycles	40	95	00:15	100	X
		64	01:00	100	Single
Cooling	1	15	∞	100	X

The emitted fluorescence must be read in the FAM (495-520 nm) and HEX (535-554 nm) channels. Both fluorescences should be detected in every well (biplex reaction).

NOTE - Set the following configuration in the Rotor-Gene® Q software:

a. Open the Rotor-Gene Q®– Pure Detection software. Select the tab "Advanced" within the "New Run" window, and click on "New".

b. Choose the "72-Well Rotor" format and check the box "Locking Ring Attached". Then, click on "Next".

c. Set the "Reaction Volume" at 20 µL and identify the operator and the samples.

d. Click on "Edit Profile" and set up the amplification program. Set the 60 sec step at 64 ºC, and click on "Acquiring to Cycling A". Set "Green" and "Yellow" as the fluorescence acquisition channels. Click on "OK" to accept and close the "Edit Profile" window.

e. Click on "Gain Optimisation" in the "Run New Wizard" dialog box to open the "Auto-Gain Optimization Setup" window. Scroll down the "Channel Settings" menu and select "Acquiring Channels". Then click on "Add". In the window "Auto-Gain Optimization Channel Settings", set the following parameters for each channel ("Green" and "Yellow"):

- Tube position = 1
- Target Sample Range: 5 FI up to 10 FI
- Acceptable Gain Range: -10 to 10

f. Check the box "Perform Optimisation Before 1st Acquisition" and click on "Close".

g. Click on "Next" and then on "Start Run" in the "New Run Wizard" window.

BDR
Blackhills Diagnostic Resources
Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

Results

The Genvinset® HLA B57v5 kit constitutes a qualitative technique to determine the presence or absence of the HLA-B*57:01 allele.

It is not necessary to select any passive reference.

The results of this technique can be obtained as follows:

B*57:01 results

Selecting the "Green" channel (FAM) in the Amplification Plot, a graphic similar to the following one can be displayed:



Samples generating an amplification curve are to be considered as B*57 positive and can be identified by a numeric value called Crossing Point (Cp), which corresponds to the cycle in which fluorescence can be detected.

ß-globin results

Selecting the "Yellow" channel (HEX/VIC) in the Amplification Plot, a graphic similar to the following one can be displayed:



Samples generating a yellow amplification curve are positive for internal control (ß-globin).

BDR
Blackhills Diagnostic Resources
Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

Quality control

Due to the qualitative nature of this test, it will not be necessary to perform a calibration.

It is recommended to perform a contamination control (Reaction Blank) by replacing the DNA for the negative control supplied in the kit and a positive control HLA-B*57:01 positive sample.

The following criteria have to be taken into account in order to validate an assay:

- The Reaction Blank should report negative results in both "Green" and "Yellow" channels. An amplification curve with a Cp>35 value should be considered as negative. A Cp<35 value is associated with a contamination in the Reaction Blank and, therefore, all results from the experiment should be discarded.
- A positive control sample must render positive results for both B*57 and for ß-globin.
- DNA samples should always be positive for ß-globin (Cp<35).
- DNA samples generating results with Cp>35 for ß-globin and/or B*57 genes must be considered as doubtful and should be re-tested performing a new DNA extraction.

The assay must be performed according to the kit recommendations, as well as other quality control procedures that comply with local, federal and/or certifying agencies specifications.

BDR
Blackhills Diagnostic Resources
Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

Specific operation data

1. Analytical specificity

The alignment of primers and probes in the most common HLA database regions (IMGT-HLA) has revealed the absence of non-specific bindings. No cross-reaction phenomena with genomic DNA have been reported.

2. Analytical sensitivity

A serial dilution assay was performed using two DNA samples (one B*57:01 positive and one B*57:01 negative), at a concentration of 9,7 and 25,8 ng/µL, respectively. Both were obtained with a conventional DNA extraction system. The following results for the analytical sensitivity of the test were obtained:

- DNA sample obtained by conventional extraction system:
  Detection Limit = 0,048 ng/µL (*)

  (*) Cp < 35

3. Diagnostic sensitivity and specificity

In three studies of human genetic DNA, one performed in an internal laboratory and two performed in external laboratories, a total of 157 samples were analysed with the Genvinset® HLA B57v5 kit. The samples had been previously typed by SSO (Sequence Specific Oligonucleotides).

All the 157 tested samples were validated (positive amplification of the ß-Globin control gene). Among those, 33 were found to be B*57:01 positive.

	Genvinset® HLA B57v5		
	Samples	B*57:01+	B*57:01-
SSO	B*57:01 +	33	0
	B*57:01 -	0	124

There is a 100% match in the results obtained with the Genvinset® HLAB57v5 kit and the previously obtained genotype with other commercial kits.

BDR
Blackhills Diagnostic Resources
Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

GenVinSet

HLA B57v5

HLA-B*57 alleles (IMGT-HLA 3.43.0) detected by Genvinset® HLA B57v5

B*57:01:01:01	B*57:01:11	B*57:01:44
B*57:01:01:02	B*57:01:12	B*57:02:01:01
B*57:01:01:03	B*57:01:13	B*57:02:01:02
B*57:01:01:04	B*57:01:15	B*57:02:02
B*57:01:01:05	B*57:01:17	B*57:03:01:01
B*57:01:01:06	B*57:01:18	B*57:03:01:02
B*57:01:01:07	B*57:01:20	B*57:03:01:03
B*57:01:01:08	B*57:01:21	B*57:03:01:04
B*57:01:01:09	B*57:01:22	B*57:03:01:05
B*57:01:01:10	B*57:01:23	B*57:03:03
B*57:01:01:11	B*57:01:24	B*57:03:04
B*57:01:01:12	B*57:01:25	B*57:03:05
B*57:01:01:13	B*57:01:26	B*57:06
B*57:01:01:14	B*57:01:27	B*57:07
B*57:01:01:15	B*57:01:28	B*57:08
B*57:01:01:16	B*57:01:29	B*57:09
B*57:01:01:17	B*57:01:31	B*57:10
B*57:01:01:18	B*57:01:32	B*57:12
B*57:01:01:19	B*57:01:33	B*57:13
B*57:01:01:20	B*57:01:34	B*57:14:02
B*57:01:02	B*57:01:35	B*57:15
B*57:01:03	B*57:01:36	B*57:16
B*57:01:04	B*57:01:37	B*57:17
B*57:01:05	B*57:01:38	B*57:18
B*57:01:06	B*57:01:39	B*57:19
B*57:01:07	B*57:01:40	B*57:20
B*57:01:08	B*57:01:41	B*57:21
B*57:01:09	B*57:01:42	B*57:22
B*57:01:10	B*57:01:43	B*57:23

i

Among all the specified list of alleles, only the HLA-B*57:01 is a frequent one. All other alleles have extremely low frequencies and are not likely to be found again in a significant number of unrelated subjets.

- Detected allele
- Non tested allele. Possible weak amplification
- *CWD alleles marked in bold and italics*

BDR
Blackhills Diagnostic Resources

Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

HLA-B*57 alleles (IMGT-HLA 3.43.0) detected by Genvinset® HLA B57v5

B*57:24
B*57:25
B*57:26
B*57:27
B*57:28N
B*57:29
B*57:30
B*57:31:01
B*57:31:02
B*57:33
B*57:34
B*57:35
B*57:36
B*57:37
B*57:38
B*57:39
B*57:40
B*57:42
B*57:43
B*57:44
B*57:45
B*57:46
B*57:47
B*57:48
B*57:49
B*57:50
B*57:51
B*57:52
B*57:53

B*57:54
B*57:55
B*57:56
B*57:57
B*57:58
B*57:59
B*57:60
B*57:61
B*57:62
B*57:63
B*57:64
B*57:65
B*57:66
B*57:67:01
B*57:67:02
B*57:68
B*57:69
B*57:70
B*57:71
B*57:72
B*57:73
B*57:74
B*57:75
B*57:76
B*57:77
B*57:78
B*57:79N
B*57:80
B*57:81

B*57:82
B*57:83
B*57:84
B*57:85
B*57:86
B*57:87
B*57:88
B*57:89
B*57:90
B*57:91
B*57:93
B*57:94
B*57:95
B*57:96
B*57:97
B*57:98Q
B*57:99
B*57:100
B*57:101
B*57:102
B*57:103
B*57:104
B*57:105
B*57:106
B*57:107
B*57:108
B*57:109
B*57:110
B*57:111

i

Among all the specified list of alleles, only the HLA-B*57:01 is a frequent one. All other alleles have extremely low frequencies and are not likely to be found again in a significant number of unrelated subjets.

- Detected allele
- Non tested allele. Possible weak amplification
- ***CWD alleles marked in bold and italics***

BDR
Blackhills Diagnostic Resources
Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

HLA-B*57 alleles (IMGT-HLA 3.43.0) detected by Genvinset® HLA B57v5

B*57:112
B*57:113
B*57:114
B*57:115
B*57:116
B*57:117
B*57:119
B*57:120
B*57:121
B*57:122N
B*57:123
B*57:124
B*57:125
B*57:126
B*57:127
B*57:128
B*57:129
B*57:130N
B*57:131
B*57:132
B*57:133
B*57:134
B*57:135
B*57:136
B*57:137
B*57:138
B*57:139N
B*57:140
B*57:141

B*58:01:05

Among all the specified list of alleles, only the HLA-B*57:01 is a frequent one. All other alleles have extremely low frequencies and are not likely to be found again in a significant number of unrelated subjets.

- Detected allele
- Non tested allele. Possible weak amplification
- ***CWD alleles marked in bold and italics***

BDR
Blackhills Diagnostic Resources
Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

Limitations of the procedure

- The current method allows for the detection of all HLA-B*57:01 allele and those specified in the previous section (IMGT-HLA 3.43.0).
- The presence of mutations or polymorphisms at the primer/probes annealing sites is possible and may result in the lack of allele definition. Alternative technologies could be necessary to resolve the typing.
- All the aforementioned conditions for the setup of the PCR should be carefully controlled. Any performances that do not meet such indications, can lead to poor results.
- All Genvinset® components manipulation must be done according to general lab best practices and be adjusted to local regulations, like the EFI standard (European Federation of Immunogenetics).
- The q-PCR thermal cycler must be calibrated and used according to the manufacturer's instructions.
- Do not mix components from other kits or lot numbers.
- Do not use the kit after its expiration date.
- Do not use the kit if there are suspicions of possible loss of reactivity, contamination, container deterioration or any other incidence that might affect the kits performance.
- Due to the complexity of HLA typing, data and result interpretation should be revised by qualified personnel.
- Discard expired reagents according to applicable regulations.

BDR
Blackhills Diagnostic Resources
Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

Troubleshooting guide

Problem

- Probable cause(s)
  - Suggested corrective measure(s).

Reaction Blank (H_2O) is positive

- Primer Mix/Master Mix/Reaction Blank contamination
  - Repeat the experiment with new Primer Mix/Master Mix/ Reaction Blank aliquots.
  - Handle the kit components always according to accepted lab practices in order to avoid contamination.
  - Verify manipulation and storage conditions.
  - Discard contaminated reagents.
- Pre-PCR area is contaminated
  - Confirm that all necessary precautions in the pre-PCR area have been followed.
  - Check for possible contamination problems in other PCR techniques.
  - Confirm suitability of the used reagents (1.5 mL tubes, pipette tips).
- Pipetting error
  - Check that the sample added corresponds to the one indicated on the worksheet.

Low or no signal in all samples. Control samples are OK.

- Samples with very low DNA concentration
  - Check the DNA concentration and repeat the extraction if necessary.
- DNA samples with high concentration
  - Perform the assay using diluted samples.

Fluorescence intensity too low

- Kit degradation (Primer Mix or Master Mix vials)
  - Check that the storage of the kit is correct, reviewing both proper temperature conditions and light exposure (which should be avoided).
  - Avoid performing more than 3 thaw/freeze cycles to the

BDR
Blackhills Diagnostic Resources
Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

reagents.

- Aliquote the reagents if necessary.
- Repeat the test with new reagents.

Negative control sample is positive

- **Cross contamination**
  - Always handle the kit components following all necessary practices to avoid contamination.
- **Pipetting error**
  - Check that the sample added corresponds to the one indicated on the worksheet.

Positive control sample is negative

- **Pipetting error**
  - Check that the sample added corresponds to the one indicated on the worksheet.

Fluorescence intensity varies

- **The dirtiness on the outside of the tube walls interferes with the signal.**
  - Handle all consumables wearing gloves.
- **Volume is not settled to the bottom of the well or there are bubbles**
  - Perform a brief centrifugation to ensure that the volume settles to the bottom of the well and to remove all bubbles.
- **Pipetting error**
  - Check that the correct volume has been added.

There is no fluorescence signal

- **Incorrect reading channels selected**
  - Set the appropriate reading channels.
- **Pipetting error or reagent absence**
  - Control the pipetting and the reaction setup.
  - Repeat the PCR.
- **No reading channel was selected in the thermal cycler program.**
  - Check and modify the thermal cycler program.

BDR
Blackhills Diagnostic Resources
Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

References

1. Saag et al. Association between presence of HLA B5701 HLA DR7 and HLA DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Clin. Infect. Dis. (2008).

*2. Saag, M. S. et al. High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin. Infect. Dis. 46, 1111–1118 (2008).*

*3. Mallal, S. et al. HLA-B*5701 Screening for Hypersensitivity to Abacavir for the PREDICT-1 Study Team* A bs t r ac t. www.nejm.org (2008).*

4. Melis, R. et al. Copy number variation and incomplete linkage disequilibrium interfere with the HCP5 genotyping assay for abacavir hypersensitivity. Genet. Test. Mol. Biomarkers 16, 1111–1114 (2012).

BDR
Blackhills Diagnostic Resources

Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

Notice to purchaser

- This product has been developed for in vitro diagnostic purposes.
- BLACKHILLS DIAGNOSTIC RESOURCES, S.L.U. products should not be re-sold, modified or be used to manufacture other commercial products without written consent of BLACKHILLS DIAGNOSTIC RESOURCES, S.L.U.
- All information contained in this document can suffer modifications without prior notice. BLACKHILLS DIAGNOSTIC RESOURCES, S.L.U. does not assume any responsibility for possible errors in the document. This document is considered complete and accurate at the time of its publication. In any case will BLACKHILLS DIAGNOSTIC RESOURCES, S.L.U. be responsible for accidental, special, multiple or derived damages from the use of this document.
- The purchase of this product grants rights to the purchaser under certain Roche patents, only used to provide in vitro diagnostic services. It does not grant any generic patent or any other patents aimed at any other usage apart from the one specified.
- FAM™ and HEX™ are trademarks of Life Technologies Corporation.
- VIC® is a registered trade mark of Life Technologies Corporation.
- FAM™, HEX™ may be covered by one or more patents owned by Applied Biosystems, LLC. The purchase price of this product includes limited, nontransferable rights.
- TaqMan® is a registered trade mark of Roche Molecular Systems, Inc.
- Genvinset® is a trade mark of BLACKHILLS DIAGNOSTIC RESOURCES, S.L.U.

BDR
Blackhills Diagnostic Resources

Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

Changes to version 01

Version	Description of the modification
Rev. 01	First document version
Rev. 02	Updating of validated qPCR thermal-cyclers.

BDR
Blackhills Diagnostic Resources
Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com

Explanation of symbols used on the labels

For in vitro diagnostic use

This product fulfills the requirements of Directive 98/79/EC on in vitro diagnostic medical device

Catalogue number

Lot number

Expiration date

Contents sufficient for <n> tests

Manufactured by

Store at

Keep away from sunlight

Positive control

BDR
Blackhills Diagnostic Resources
Cno. del Pilón 86, Casa 7 Local
50011- Zaragoza - Spain
www.bdrdiagnostics.com